Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. An imprecise understanding of the immunologic changes underlying sarcoidosis has limited therapeutic progress. Here in this open-label trial (NCT03910543), 10 patients with cutaneous sarcoidosis are tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Damsky, William, Wang, Alice, Kim, Daniel J., Young, Bryan D., Singh, Katelyn, Murphy, Michael J., Daccache, Joseph, Clark, Abigale, Ayasun, Ruveyda, Ryu, Changwan, McGeary, Meaghan K., Odell, Ian D., Fazzone-Chettiar, Ramesh, Pucar, Darko, Homer, Robert, Gulati, Mridu, Miller, Edward J., Bosenberg, Marcus, Flavell, Richard A., King, Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170782/
https://www.ncbi.nlm.nih.gov/pubmed/35668129
http://dx.doi.org/10.1038/s41467-022-30615-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170782/
https://www.ncbi.nlm.nih.gov/pubmed/35668129
http://dx.doi.org/10.1038/s41467-022-30615-x

Ejemplares similares